Drugs / generalized modules for membrane antigens (GMMA)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05630859 | Nov 2022 → May 2025 | sexually transmitted disease | GlaxoSmithKline | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | generalized modules for membrane antigens (GMMA) | “GlaxoSmithKline's (GSK) Neisseria gonorrhoeae generalized modules for membrane antigens (GMMA) (NgG) investigational vaccine” NCT05630859 ↗ |
| Known as | NgG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05630859 ↗ |
| Modality | Vaccine | “GSK Neisseria gonorrhoeae generalized modules for membrane antigens (GMMA) (NgG) investigational vaccine” NCT05630859 ↗ |
| Route | Intramuscular | “2 doses of NgG 12.5 µg investigational vaccine administered intramuscularly.” NCT05630859 ↗ |